Friday, January 18, 2008

Forbes on Medicis, "aesthetics" industry

Forbes discussed the interaction between Medicis and Impax over Solodyn, a drug used to treat acne.

Within the article were the following:

Bioequivalence, a standard required by the FDA in order to receive approval for a generic drug, means that the active ingredient in a medication be absorbed and metabolized in a comparable amount to the active ingredient in the brand name drug. Medicis hopes that recent changes in bioequivalence standards will work to its advantage.


James Arthur Kelly notes that Medicis is facing tough challenges in 2008 as the "consumer slowdown could affect the aesthetics business and spending will increase to prepare for the Reloxin launch at year-end." Reloxin is another skincare treatment used to alleviate aging signs like wrinkles.


Post a Comment

<< Home